NEMAURA
Live / Registered — Registered — partial invalidation of extension of protection (as of 23 May 2024)
What this means for you
Registered since 26 Sept 2017. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79185414
- Registration number
- 5293350
- Mark type
- Stylized text
- Filed
- 24 Dec 2015
- Published for opposition
- 11 Jul 2017
- Registered
- 26 Sept 2017
- Attorney of record
- Ali R. Latifi
Goods and services
- Class 005 — Pharmaceuticals: [ Pharmaceutical and veterinary preparations for treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Sanitary preparations for medical purposes; Diagnostic preparations and substances for medical or veterinary purposes; Medical diagnostic reagents; Antiserums for medical or veterinary diagnostic purposes; Vaccines for human beings and animals; Adjuvants for use with vaccines; Biological laboratory preparations for medical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Chemical preparations and reagents for medical, pharmaceutical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Viruses for the treatment of humans and animals for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Diagnostic preparations for medical purposes; In-vitro diagnostics for medical purposes; In-vivo diagnostics for medical purposes; Medical plasters; Transdermal patches for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal plasters for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal therapeutic drug delivery systems (TTS), namely, transdermal patches and plasters treated or impregnated with pharmaceutical active ingredients for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Medicated transdermal drug delivery patches featuring medication for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Vaccines; Drug delivery agents in the form of dissolvable films, coatings for tablets, capsules that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for injection in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Drug delivery agents in the form of liquid medications, tablets, powders, capsules, inhalants, nasal sprays, orally disintegrating tablets, and mouthwashes that facilitate the delivery of pharmaceutical preparations; Balms for medical purposes; Tonics for medical purposes, namely, for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Disinfectants, antiseptics ]
- Class 010 — Medical apparatus: [ Surgical apparatus and instruments for medical, dental or veterinary use; Suture materials; Inhalers for medical purposes; Filters for inhalers for medical purposes; Inhalers for medical use; Inhalers for therapeutic use; Electromagnetic drug delivery apparatus for medical use; Drug delivery apparatus and devices, namely, medical apparatus and units for dosage, measuring and monitoring; Microneedle arrays for delivering medications; Hypodermic syringes for injections for medical purposes; Electrical drug delivery apparatus for medical use; Needles for medical and surgical use; Hypodermic needles ]
- Class 042 — Scientific and technological services: Medical research services; Conducting clinical trials for others; Medical research laboratory services; Medical research laboratory services for the analysis of samples taken from patients; Scientific analysis and research services, namely, DNA analysis services for scientific research purposes; Product development relating to pharmaceuticals, medicines, medicaments and veterinary products; Medical and health care testing services for research purposes, namely, clinical testing services, physician testing services for assisting pharmacists, pharmaceutical testing services, and medical laboratory and testing services; Pharmaceutical research and development services; Medical and scientific research information in the field of healthcare; Cosmetics research; Design and development of computer hardware and software and information storage retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease
Owner
- Nemaura Pharma Limited, Leicestershire, GB
- Nemaura Pharma Limited, GB
- Nemaura Pharma Limited, GB
Prosecution history
- 06 Jun 2025 — PARTIAL INVALIDATION PROCESSED BY THE IB
- 24 Apr 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 11 Apr 2025 — PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
- 11 Apr 2025 — INVALIDATION PROCESSED
- 23 Jan 2025 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 23 May 2024 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 23 May 2024 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 20 May 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Sept 2023 — TEAS SECTION 71 RECEIVED
- 26 Sept 2022 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 10 Feb 2018 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 12 Jan 2018 — FINAL DISPOSITION NOTICE SENT TO IB
- 12 Jan 2018 — FINAL DISPOSITION PROCESSED
- 26 Dec 2017 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 01 Dec 2017 — NEW REPRESENTATIVE AT IB RECEIVED